FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3171718900> ?p ?o ?g. }

• W3171718900 endingPage "e2115985" @default.
• W3171718900 startingPage "e2115985" @default.
• W3171718900 abstract "<h3>Importance</h3> The BNT162b2 vaccine showed high efficacy against COVID-19 in a phase III randomized clinical trial. A vaccine effectiveness evaluation in a real-world setting is needed. <h3>Objective</h3> To assess the short-term effectiveness of the first dose of the BNT162b2-vaccine against SARS-CoV-2 infection 13 to 24 days after immunization in a real-world setting. <h3>Design, Setting, and Participants</h3> This comparative effectiveness study used data from a 2.6 million-member state-mandated health care system in Israel. Participants included all individuals aged 16 years and older who received 1 dose of the BNT162b2 vaccine between December 19, 2020, and January 15, 2021. Data were analyzed in March 2021. <h3>Exposure</h3> Receipt of 1 dose of the BNT162b2 vaccine. <h3>Main Outcomes and Measures</h3> Information was collected regarding medical history and positive SARS-CoV-2 polymerase chain reaction test and COVID-19 symptoms from 1 day after first vaccine to January 17, 2021. Daily and cumulative infection rates in days 13 to 24 were compared with days 1 to 12 after the first dose using Kaplan-Meier survival analysis and generalized linear models. <h3>Results</h3> Data for 503 875 individuals (mean [SD] age, 59.7 [14.7] years; 263 228 [52.4%] women) were analyzed, of whom 351 897 had follow-up data for days 13 to 24. The cumulative incidence of SARS-CoV-2 infection was 2484 individuals (0.57%) during days 1 through 12 and 614 individuals (0.27%) in days 13 through 24. The weighted mean (SE) daily incidence of SARS-CoV-2 infection in days 1 through 12 was 43.41 (12.07) infections per 100 000 population and 21.08 (6.16) infections per 100 000 population in days 13 through 24, a relative risk reduction (RRR) of 51.4% (95% CI, 16.3%-71.8%). The decrease in incidence was evident from day 18 after the first dose. Similar RRRs were calculated in individuals aged 60 years or older (44.5%; 95% CI, 4.1%-67.9%), those younger than 60 years (50.2%; 95% CI, 14.1%-71.2%), women (50.0%; 95% CI, 13.5%-71.0%), and men (52.1%; 95% CI, 17.3%-72.2%). Findings were similar in subpopulations (eg, ultraorthodox Jewish: RRR, 53.5% [95% CI, 19.2%-73.2%]) and patients with various comorbidities (eg, cardiovascular diseases: RRR, 47.2% [95% CI, 7.8%-69.8%]). Vaccine effectiveness against symptomatic COVID-19 was 54.4% (95% CI, 21.4%-73.6%). <h3>Conclusions and Relevance</h3> In this comparative effectiveness study of a single dose of the BNT162b2 vaccine, results were comparable to that of the phase III randomized clinical trial." @default.
• W3171718900 created "2021-06-22" @default.
• W3171718900 creator A5004950632 @default.
• W3171718900 creator A5034265331 @default.
• W3171718900 creator A5055748135 @default.
• W3171718900 creator A5061426528 @default.
• W3171718900 creator A5063419991 @default.
• W3171718900 creator A5071620914 @default.
• W3171718900 creator A5076126189 @default.
• W3171718900 date "2021-06-07" @default.
• W3171718900 modified "2023-10-13" @default.
• W3171718900 title "Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization" @default.
• W3171718900 cites W1963641435 @default.
• W3171718900 cites W2098380460 @default.
• W3171718900 cites W2162124703 @default.
• W3171718900 cites W2170034816 @default.
• W3171718900 cites W2773540893 @default.
• W3171718900 cites W3093367571 @default.
• W3171718900 cites W3109022689 @default.
• W3171718900 cites W3111255098 @default.
• W3171718900 cites W3119846258 @default.
• W3171718900 cites W3131688063 @default.
• W3171718900 doi "https://doi.org/10.1001/jamanetworkopen.2021.15985" @default.
• W3171718900 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8185600" @default.
• W3171718900 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34097044" @default.
• W3171718900 hasPublicationYear "2021" @default.
• W3171718900 type Work @default.
• W3171718900 sameAs 3171718900 @default.
• W3171718900 citedByCount "92" @default.
• W3171718900 countsByYear W31717189002021 @default.
• W3171718900 countsByYear W31717189002022 @default.
• W3171718900 countsByYear W31717189002023 @default.
• W3171718900 crossrefType "journal-article" @default.
• W3171718900 hasAuthorship W3171718900A5004950632 @default.
• W3171718900 hasAuthorship W3171718900A5034265331 @default.
• W3171718900 hasAuthorship W3171718900A5055748135 @default.
• W3171718900 hasAuthorship W3171718900A5061426528 @default.
• W3171718900 hasAuthorship W3171718900A5063419991 @default.
• W3171718900 hasAuthorship W3171718900A5071620914 @default.
• W3171718900 hasAuthorship W3171718900A5076126189 @default.
• W3171718900 hasBestOaLocation W31717189001 @default.
• W3171718900 hasConcept C120665830 @default.
• W3171718900 hasConcept C121332964 @default.
• W3171718900 hasConcept C126322002 @default.
• W3171718900 hasConcept C147483822 @default.
• W3171718900 hasConcept C168563851 @default.
• W3171718900 hasConcept C187212893 @default.
• W3171718900 hasConcept C203014093 @default.
• W3171718900 hasConcept C22070199 @default.
• W3171718900 hasConcept C2779134260 @default.
• W3171718900 hasConcept C2780689484 @default.
• W3171718900 hasConcept C2780801004 @default.
• W3171718900 hasConcept C3007834351 @default.
• W3171718900 hasConcept C3008058167 @default.
• W3171718900 hasConcept C524204448 @default.
• W3171718900 hasConcept C535046627 @default.
• W3171718900 hasConcept C61511704 @default.
• W3171718900 hasConcept C71924100 @default.
• W3171718900 hasConcept C72563966 @default.
• W3171718900 hasConcept C88879693 @default.
• W3171718900 hasConceptScore W3171718900C120665830 @default.
• W3171718900 hasConceptScore W3171718900C121332964 @default.
• W3171718900 hasConceptScore W3171718900C126322002 @default.
• W3171718900 hasConceptScore W3171718900C147483822 @default.
• W3171718900 hasConceptScore W3171718900C168563851 @default.
• W3171718900 hasConceptScore W3171718900C187212893 @default.
• W3171718900 hasConceptScore W3171718900C203014093 @default.
• W3171718900 hasConceptScore W3171718900C22070199 @default.
• W3171718900 hasConceptScore W3171718900C2779134260 @default.
• W3171718900 hasConceptScore W3171718900C2780689484 @default.
• W3171718900 hasConceptScore W3171718900C2780801004 @default.
• W3171718900 hasConceptScore W3171718900C3007834351 @default.
• W3171718900 hasConceptScore W3171718900C3008058167 @default.
• W3171718900 hasConceptScore W3171718900C524204448 @default.
• W3171718900 hasConceptScore W3171718900C535046627 @default.
• W3171718900 hasConceptScore W3171718900C61511704 @default.
• W3171718900 hasConceptScore W3171718900C71924100 @default.
• W3171718900 hasConceptScore W3171718900C72563966 @default.
• W3171718900 hasConceptScore W3171718900C88879693 @default.
• W3171718900 hasIssue "6" @default.
• W3171718900 hasLocation W31717189001 @default.
• W3171718900 hasLocation W31717189002 @default.
• W3171718900 hasLocation W31717189003 @default.
• W3171718900 hasOpenAccess W3171718900 @default.
• W3171718900 hasPrimaryLocation W31717189001 @default.
• W3171718900 hasRelatedWork W1970343129 @default.
• W3171718900 hasRelatedWork W1989442283 @default.
• W3171718900 hasRelatedWork W2002551728 @default.
• W3171718900 hasRelatedWork W2516211728 @default.
• W3171718900 hasRelatedWork W3010794731 @default.
• W3171718900 hasRelatedWork W3033306779 @default.
• W3171718900 hasRelatedWork W3196249313 @default.
• W3171718900 hasRelatedWork W4298981981 @default.
• W3171718900 hasRelatedWork W4299841576 @default.
• W3171718900 hasRelatedWork W4301681852 @default.
• W3171718900 hasVolume "4" @default.
• W3171718900 isParatext "false" @default.
• W3171718900 isRetracted "false" @default.

• next